매출 성장 + 마진 확대 + FCF 양수
Positive매출이 +5.5% 성장하면서 영업이익률이 10.5%에서 12.0%로 확대되었다. FCF도 양수를 유지하여 질적 성장이 확인된다.
Evidence
매출 YoY +5.5%영업이익률 10.5%→12.0%FCF 7,647
KD Chem
A221980 · KOSDAQ₩9,250-0.43%
2026-08-03 closeKD Chem — pricey right now, or cheap? And what signals are flashing today?
Open the exact grade & valuation bands with Pro →Loading chart…
Close
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
Strong-buy signal — the real recordrecord · not a prediction
Not this one stock, but every strong-buy pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)
Last 30 sessions
648 picks
Next-day win rate
49.2%
Avg next-day
-0.17%
vs market
+0.72%p
Beat the market on 62.1% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
07-31 0%07-30 66.7%07-29 0%07-28 45%07-27 20%07-25 36.4%07-21 55.6%07-20 53.8%07-16 53.3%07-15 50%07-14 71.4%07-13 31.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Valuation Grades
Relative to 110 화학 peers · not investment advice
Valuation in its own history
PER 6.93 · PBR 0.37 — own history (2015-11~) percentiles 75/100 · 100/100
PER75/100
PBR100/100
Higher indicates lower valuation relative to its history (based on earnings and book yields).
Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.
Annual dividend
Split-adjusted annual DPS history and available grade axes
Paid 10 consecutive years · Raised 0 consecutive years · Yield 5.41% (based on 2025 payment of 500원) · 3-year growth +0.0%
Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 8.19
Distress
Grey
Safe
- Altman Z''
- 8.19
- Beneish M-Score
- -3.05
- Sloan accrual
- -1.25%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
4/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score4/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginPass
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Industry structure
KRAs of 2026-08-03화학
This stock is in 화학: revenue rank 86 of 109, share 0%.
86 / 1090%revenue share
Who dominates this industry?
- 1LG화학31.9%
- 2롯데케미칼13.3%
- 3금호석유화학4.7%
- 4DL3.7%
- 5코오롱인더3.2%
- 6케이디켐0%
Concentration
DistributedCR3 49.9%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
MixedConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 8.66
- Direction
- 확대
- Level
- 보통
- Years
- 6
Value lens
- P90/P10
- 9.3
- Median P/B
- 0.71
- Level
- 넓음
- n
- 98
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 12%
- Interest coverage
- 9.7x
- Return on equity (ROE)
- 5.3%
Operating margin −5pp
TolerableInterest coverageBase 9.7x adverse case 5.6x
Return on equity (ROE)Base 5.3% adverse case 3.5%
Revenue −15%
TolerableInterest coverageBase 9.7x adverse case 8.2x
Return on equity (ROE)Base 5.3% adverse case 5.5%
Interest rate +2pp
TolerableInterest coverageBase 9.7x adverse case 5.4x
Return on equity (ROE)Base 5.3% adverse case 6%
Interest coverage limit
Current margin 10.7ppInterest coverage limit at an operating margin of 1.2%
Interest expense coverage threshold
Financials at a glance
KD Chem's latest results and balance sheet. The bars track the last three periods.
Connections
AI-extracted related companies · for reference
Customers
LG화학Price comovement r=0.07 (1 year)한화솔루션Price comovement r=0.12 (1 year)롯데케미칼Price comovement r=0.16 (1 year)SKCPrice comovement r=0.11 (1 year)효성첨단소재코오롱인더Price comovement r=0.17 (1 year)금호석유화학Price comovement r=0.13 (1 year)대한유화Price comovement r=0.12 (1 year)애경케미칼Price comovement r=0.02 (1 year)OCIPrice comovement r=0.07 (1 year)
Recent filings
KD Chem's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy